Table 3.

Infection Outcomes

Infection Type	Ruxolitinib naïve (N=73)	Ruxolitinib treated (N=202)	Total (N=275)	P Value
Infection, Yes, N(%)	28 (38.4%)	86 (42.6%)	114 (41.5%)	0.531
Respiratory
Viral upper respiratory infection	12 (16.4%)	26 (12.8%)	38 (13.8%)
Pneumonia, bacterial	0 (0%)	12 (5.9%)	12 (4.4%)
Pneumonia, atypical	0 (0%)	2 (0.9%)	2 (0.7%)
Influenza	0 (0%)	1 (0.4%)	1 (0.4%)
Pulmonary tuberculosis	0 (0%)	1 (0.4%)	1 (0.4%)
Urinary
Cystitis	5 (6.8%)	9 (4.4%)	14 (5.1%)
Pyelonephritis	1 (1.3%)	0 (0%)	1 (0.4%)
Skin and Soft Tissue
Herpes zoster	2 (2.7%)	8 (3.9%)	10 (3.6%)
Cellulitis	2 (2.7%)	2 (0.9%)	4 (1.5%)
Herpes simplex virus	0 (0%)	2 (0.9%)	2 (0.7%)
Skin abscess	0 (0%)	1 (0.4%)	1 (0.4%)
Fungal rash	0 (0%)	1 (0.4%)	1 (0.4%)
Gastrointestinal
Clostridium difficile	0 (0%)	4 (1.9%)	4 (1.5%)
Diverticulitis	1 (1.3%)	3 (1.4%)	4 (1.5%)
Enteritis	0 (0%)	1 (0.4%)	1 (0.4%)
Proctitis	0 (0%)	1 (0.4%)	1 (0.4%)
Norovirus	0 (0%)	1 (0.4%)	1 (0.4%)
Oral, Ocular, and Sinuses
Dental abscess	2 (2.7%)	4 (1.9%)	6 (2.2%)
Bacterial conjunctivitis	0 (0%)	2 (0.9%)	2 (0.7%)
Sinusitis	1 (1.3%)	1 (0.4%)	2 (0.7%)
Otitis media	0 (0%)	1 (0.4%)	1 (0.4%)
Mucositis	0 (0%)	1 (0.4%)	1 (0.4%)
Miscellaneous
Bacteremia	1 (1.3%)	3 (1.4%)	4 (1.5%)
Septic shock (unknown source)	1 (1.3%)	1 (0.4%)	2 (0.7%)
Osteomyelitis	0 (0%)	1 (0.4%)	1 (0.4%)
Lyme disease	0 (0%)	1 (0.4%)	1 (0.4%)
Infection Grade, N(%)				0.813
1	5 (6.8%)	9 (4.5%)	14 (5.1%)
2	16 (21.9%)	46 (22.8%)	62 (22.5%)
3	6 (8.2%)	26 (12.9%)	32 (11.6%)
4	1 (1.4%)	4 (2.0%)	5 (1.8%)
5	0 (0.0%)	1 (0.5%)	1 (0.4%)
Hospitalization Secondary to Infection, N(%)	7 (9.6%)	30 (14.9%)	37 (13.5%)	0.259
Documented Recurrent Infection, N(%)	1 (1.4%)	29 (14.4%)	30 (10.9%)	0.002